About Charles River Laboratories International, Inc.
https://www.criver.comCharles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
CEO
James C. Foster
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 426
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
TD Cowen
Buy
Jefferies
Buy
Citigroup
Buy
Redburn Atlantic
Buy
Baird
Outperform
William Blair
Outperform
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:50.46M
Value:$10.92B
VANGUARD GROUP INC
Shares:5.84M
Value:$1.26B
BLACKROCK INC.
Shares:5.09M
Value:$1.1B
Summary
Showing Top 3 of 763
About Charles River Laboratories International, Inc.
https://www.criver.comCharles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1B ▼ | $204.99M ▼ | $54.42M ▲ | 5.42% ▲ | $1.11 ▲ | $197.77M ▼ |
| Q2-2025 | $1.03B ▲ | $256.93M ▲ | $52.33M ▲ | 5.07% ▲ | $1.06 ▲ | $220.89M ▲ |
| Q1-2025 | $984.17M ▼ | $243.06M ▼ | $25.47M ▲ | 2.59% ▲ | $0.5 ▲ | $184.23M ▲ |
| Q4-2024 | $1B ▼ | $451.93M ▲ | $-215.7M ▼ | -21.52% ▼ | $-4.22 ▼ | $-86.45M ▼ |
| Q3-2024 | $1.01B | $231.62M | $68.68M | 6.8% | $1.34 | $209.72M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $207.67M ▲ | $7.51B ▼ | $4.06B ▼ | $3.41B ▲ |
| Q2-2025 | $182.82M ▼ | $7.56B ▼ | $4.16B ▼ | $3.35B ▲ |
| Q1-2025 | $229.36M ▲ | $7.58B ▲ | $4.34B ▲ | $3.19B ▼ |
| Q4-2024 | $194.61M ▼ | $7.53B ▼ | $4.02B ▼ | $3.46B ▼ |
| Q3-2024 | $210.17M | $8B | $4.18B | $3.78B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $55.56M ▲ | $213.83M ▲ | $-33.7M ▲ | $-152.62M ▲ | $24.48M ▲ | $178.25M ▲ |
| Q2-2025 | $52.69M ▲ | $204.6M ▲ | $-37.34M ▲ | $-226.92M ▼ | $-46.99M ▼ | $169.31M ▲ |
| Q1-2025 | $25.88M ▲ | $171.7M ▲ | $-45.48M ▲ | $-105.33M ▼ | $26.16M ▲ | $112.37M ▲ |
| Q4-2024 | $-213.75M ▼ | $159.36M ▼ | $-76.1M ▼ | $-75.88M ▲ | $-6.07M ▼ | $83.75M ▼ |
| Q3-2024 | $70.3M | $251.79M | $-21.32M | $-207.54M | $30.64M | $213.07M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Discovery and Safety Assessment | $600.00M ▲ | $590.00M ▼ | $620.00M ▲ | $600.00M ▼ |
 Manufacturing Support | $190.00M ▲ | $180.00M ▼ | $200.00M ▲ | $190.00M ▼ |
 Research Models and Services | $200.00M ▲ | $210.00M ▲ | $210.00M ▲ | $210.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Asia Pacific | $60.00M ▲ | $50.00M ▼ | $40.00M ▼ | $50.00M ▲ |
 CANADA | $120.00M ▲ | $120.00M ▲ | $130.00M ▲ | $140.00M ▲ |
 Europe | $260.00M ▲ | $280.00M ▲ | $260.00M ▼ | $280.00M ▲ |
 UNITED STATES | $550.00M ▲ | $540.00M ▼ | $540.00M ▲ | $550.00M ▲ |
CEO
James C. Foster
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 426
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
TD Cowen
Buy
Jefferies
Buy
Citigroup
Buy
Redburn Atlantic
Buy
Baird
Outperform
William Blair
Outperform
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:50.46M
Value:$10.92B
VANGUARD GROUP INC
Shares:5.84M
Value:$1.26B
BLACKROCK INC.
Shares:5.09M
Value:$1.1B
Summary
Showing Top 3 of 763